Tempus AI, Inc. (TEM): Debts to Book Capitalization

Graphic logo of Tempus Labs (TEM)

Despite its reliance on cloud IT providers for data processing, Tempus AI, Inc (TEM) is implementing advanced precision medicine to personalize oncology treatment. Fluctuations in the debt-to-equity ratio demonstrate the financial resilience of the strategy, where 3.43 represents the current metric. This supports the development of an ecosystem that connects clinics and pharma behemoths through genomic analysis within a strict regulatory framework.

TEM (Tempus AI, Inc.) Debt to Book Value history from 06/15/2024 to 10/27/2026
Product sample of tempus.com

Tempus AI, Inc (TEM) must balance aggressive growth with financial stability given its status as a bold pioneer in AI genetics. This metric measures the proportion of debt relative to equity, allowing for an assessment of the debt load and bankruptcy risk, which makes the debt-to-capitalization ratio a key indicator of investment safety amidst the technological hype.

Competitors of Tempus AI, Inc

Debt to Book Value Qiagen N.V. (QGEN)|Debt to Book Capital ionispharma.com IONS|RGEN (Repligen) - Debts to Book Capitalization|RNA: Debts to Book Value|CRSP (CRISPR Therapeutics Corp) - Debt to Book Capitalization Ratio|WGS (GeneDx Corp) - Debt to Book Value|Debt to Book Capitalization Ratio Ultragenyx Pharmaceutical RARE|Debts to Book Capitalization Ratio beamtx.com (BEAM)|Debt to Book Value SRPT|Debts to Book Capitalization TWST (Twist Bioscience Inc)|Debt to Book Capitalization Ratio TXG|NTLA - Debts to Net Assets|Debt to Book Value Stoke Therapeutics (STOK)|BLFS - Debt to Net Assets Ratio|WVE: Debts to Book Capitalization|Maze Therapeutics, Inc. (MAZE) - Debts to Book Capitalization|SION: Debts to Book Capitalization|Debts to Net Assets Prime Medicine Bio (PRME)|Taysha Gene Therapies (TSHA) - Debt to Book Value|Debt to Net Assets Ratio uniqure.com (QURE)|Debts to Book Capitalization MGTX|REGENXBIO Inc - Debts to Net Assets|Solid Bio (SLDB) - Debt to Book Capitalization Ratio|OCGN - Debt to Book Value Ratio|PACB (Pacific Biosciences) - Debts to Book Capitalization|Debt to Book Value benitec.com|Design Therapeutics, Inc. (DSGN) - Debt to Book Value|Debt to Book Capital Rocket Pharma|4D Molecular Therapeutics Inc - Debts to Book Capitalization|Debts to Book Value LXEO (lexeotx.com)|Korro Bio - Debt to Book Capitalization Ratio|Debt to Book Value editasmedicine.com EDIT|Silence Therapeutics plc (SLN) - Debts to Book Capitalization|PRQR: Debt to Book Value Ratio|Debt to Book Capitalization Ratio codexis.com|Sangamo BioSciences (SGMO) - Debt to Book Value Ratio|NAUT (Nautilus Biotechnology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization metagenomi.co (MGX)|Debt to Book Value Precision BioSciences, Inc.|Debt to Book Capital generationbio.com (GBIO)|BOLD: Debts to Book Capitalization|Exicure Inc. - Debts to Book Value|IMNN: Debt to Book Capitalization Ratio|PHIO: Debt to Book Value|Debt to Book Capitalization Ratio mustangbio.com (MBIO)|Debts to Book Capitalization Ratio TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - Debt to Book Value|Debts to Book Capitalization APDN|BLUE (bluebird bio, Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets immunoprecise.com IPA|Debt to Book Value Omega Therapeutics, Inc.|Debt to Net Assets Ratio Singular Genomics Systems, Inc. OMIC|Regulus Therapeutics Inc - Debts to Book Capitalization|SYRS - Debts to Book Capitalization|Telesis Bio, Inc. - Debts to Book Capitalization|Debts to Net Assets traconpharma.com|UBX - Debt to Book Value